Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.

Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand'Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrj M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T.

Mult Scler Relat Disord. 2019 Nov 25;38:101868. doi: 10.1016/j.msard.2019.101868. [Epub ahead of print]

PMID:
31877445
2.

Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis.

Nasi M, Bianchini E, De Biasi S, Gibellini L, Neroni A, Mattioli M, Pinti M, Iannone A, Mattioli AV, Simone AM, Ferraro D, Vitetta F, Sola P, Cossarizza A.

J Neuroimmunol. 2020 Jan 15;338:577107. doi: 10.1016/j.jneuroim.2019.577107. Epub 2019 Nov 7.

PMID:
31726376
3.

Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis.

Ferraro D, Trovati A, Bedin R, Natali P, Franciotta D, Santangelo M, Camera V, Vitetta F, Varani M, Trenti T, Gastaldi M, De Biasi S, Nasi M, Pinti M, Meletti S, Sola P.

Eur J Neurol. 2020 Mar;27(3):461-467. doi: 10.1111/ene.14121. Epub 2019 Dec 2.

PMID:
31710409
4.

Tracing underground sources of pollution to coastal waters off Map Ta Phut, Rayong, Thailand.

Burnett WC, Sola P, Chanyotha S, Bidorn B, Kritsananuwat R, Chinfak N.

Mar Pollut Bull. 2019 Nov;148:75-84. doi: 10.1016/j.marpolbul.2019.07.071. Epub 2019 Aug 6.

PMID:
31422306
5.

Risk of secondary progressive multiple sclerosis: A longitudinal study.

Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T.

Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9.

PMID:
31397221
6.

Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients.

De Biasi S, Simone AM, Bianchini E, Lo Tartaro D, Pecorini S, Nasi M, Patergnani S, Carnevale G, Gibellini L, Ferraro D, Vitetta F, Pinton P, Sola P, Cossarizza A, Pinti M.

Eur J Immunol. 2019 Dec;49(12):2204-2221. doi: 10.1002/eji.201948223. Epub 2019 Aug 16.

PMID:
31373677
7.

ATRX-DAXX Complex Expression Levels and Telomere Length in Normal Young and Elder Autopsy Human Brains.

Cavalcante SG, Silva CPN, Sola PR, Tanaka LY, Oba-Shinjo SM, Marie SKN.

DNA Cell Biol. 2019 Sep;38(9):955-961. doi: 10.1089/dna.2019.4752. Epub 2019 Jul 30.

PMID:
31361513
8.

Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients.

Ferraro D, Guicciardi C, De Biasi S, Pinti M, Bedin R, Camera V, Vitetta F, Nasi M, Meletti S, Sola P.

Acta Neurol Scand. 2020 Jan;141(1):16-21. doi: 10.1111/ane.13152. Epub 2019 Aug 26.

PMID:
31350854
9.

The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.

Curti E, Tsantes E, Baldi E, Caniatti LM, Ferraro D, Sola P, Granella F.

Mult Scler Relat Disord. 2019 Aug;33:146-152. doi: 10.1016/j.msard.2019.05.026. Epub 2019 May 31.

PMID:
31200271
10.

Solubilization of Carbamazepine in TPGS Micelles: Effect of Temperature and Electrolyte Addition.

Jain S, Pandey S, Sola P, Pathan H, Patil R, Ray D, Aswal VK, Bahadur P, Tiwari S.

AAPS PharmSciTech. 2019 May 28;20(5):203. doi: 10.1208/s12249-019-1412-1.

PMID:
31139965
11.

Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study.

Annunziata P, Masi G, Cioni C, Gastaldi M, Marchioni E, D'amico E, Patti F, Laroni A, Mancardi G, Vitetta F, Sola P.

Neurol Sci. 2019 Jul;40(7):1383-1391. doi: 10.1007/s10072-019-03830-6. Epub 2019 Mar 22.

PMID:
30903415
12.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

13.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.

PMID:
30636699
14.

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, Terzi M, Alroughani R, Duquette P, Girard M, Prat A, Boz C, Sola P, Ferraro D, Lugaresi A, Lechner-Scott J, Barnett M, Grand'Maison F, Grammond P, Ramo-Tello C, Turkoglu R, McCombe P, Pucci E, Trojano M, Granella F, Spitaleri D, Van Pesch V, Soysal A, Oreja-Guevara C, Verheul F, Vucic S, Hodgkinson S, Slee M, Ampapa R, Prevost J, Menoyo JLS, Skibina O, Solaro C, Olascoaga J, Shaw C, Madsen KG, Naidoo K, Hyde R, Butzkueven H, Jokubaitis V; MSBase Study Group.

Mult Scler Relat Disord. 2019 Feb;28:235-243. doi: 10.1016/j.msard.2019.01.003. Epub 2019 Jan 3.

PMID:
30623864
15.

Prion-related peripheral neuropathy in sporadic Creutzfeldt-Jakob disease.

Baiardi S, Redaelli V, Ripellino P, Rossi M, Franceschini A, Moggio M, Sola P, Ladogana A, Fociani P, Magherini A, Capellari S, Giese A, Caughey B, Caroppo P, Parchi P.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):424-427. doi: 10.1136/jnnp-2018-319221. Epub 2018 Oct 24.

PMID:
30355606
16.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Hupperts R, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Sola P, Ferraro D, Trojano M, Ramo-Tello C, Lechner-Scott J, Pucci E, Solaro C, Slee M, Van Pesch V, Sanchez Menoyo JL, van der Walt A, Butzkueven H, Kappos L, Kalincik T; MSBase Study Group.

Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.

PMID:
30298572
17.

Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.

Min M, Spelman T, Lugaresi A, Boz C, Spitaleri D, Pucci E, Grand'Maison F, Granella F, Izquierdo G, Butzkueven H, Sanchez-Menoyo JL, Barnett M, Girard M, Trojano M, Grammond P, Duquette P, Sola P, Alroughani R, Hupperts R, Vucic S, Kalincik T, Van Pesch V, Lechner-Scott J.

Mult Scler. 2018 Oct;24(12):1569-1577. doi: 10.1177/1352458518798147. Epub 2018 Sep 20.

PMID:
30234431
18.

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, Lugaresi A, Grammond P, Sola P, Ferraro D, Grand'Maison F, Alroughani R, Terzi M, Boz C, Hupperts R, Lechner-Scott J, Kappos L, Pucci E, Hodgkinson S, Solaro C, Butzkueven H.

J Neurol Sci. 2018 Aug 15;391:72-76. doi: 10.1016/j.jns.2018.06.001. Epub 2018 Jun 2.

PMID:
30103975
19.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Slee M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambiatos A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.

20.

Prevalence of Hypodontia in a Sample of Spanish Dental Patients.

Sola RA, Sola PA, Pérez JC, Sánchez IN, Renovales ID.

Acta Stomatol Croat. 2018 Mar;52(1):18-23. doi: 10.15644/asc52/1/3.

21.

Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.

Ferraro D, Camera V, Vitetta F, Zennaro M, Ciolli L, Nichelli PF, Sola P.

Neurology. 2018 May 1;90(18):852-854. doi: 10.1212/WNL.0000000000005417. Epub 2018 Mar 30. No abstract available.

PMID:
29602915
22.

First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.

Ferraro D, Camera V, Baldi E, Vacchiano V, Curti E, Guareschi A, Malagù S, Montepietra S, Strumia S, Santangelo M, Caniatti L, Foschi M, Lugaresi A, Granella F, Pesci I, Motti L, Neri W, Immovilli P, Montanari E, Vitetta F, Simone AM, Sola P.

Curr Med Res Opin. 2018 Oct;34(10):1803-1807. doi: 10.1080/03007995.2018.1451311. Epub 2018 Apr 12.

PMID:
29526118
23.

Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Frau J, Villar LM, Sardu C, Secci MA, Schirru L, Ferraro D, Coghe G, Lorefice L, Fenu G, Bedin R, Sola P, Marrosu MG, Cocco E.

J Neurol. 2018 Feb;265(2):424-430. doi: 10.1007/s00415-017-8716-4. Epub 2017 Dec 22.

PMID:
29273846
24.

Systematic assessment and characterization of chronic pain in multiple sclerosis patients.

Ferraro D, Plantone D, Morselli F, Dallari G, Simone AM, Vitetta F, Sola P, Primiano G, Nociti V, Pardini M, Mirabella M, Vollono C.

Neurol Sci. 2018 Mar;39(3):445-453. doi: 10.1007/s10072-017-3217-x. Epub 2017 Dec 9.

PMID:
29224058
25.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
26.

Cerebrospinal fluid analysis and the determination of oligoclonal bands.

Gastaldi M, Zardini E, Leante R, Ruggieri M, Costa G, Cocco E, De Luca G, Cataldo I, Biagioli T, Ballerini C, Castellazzi M, Fainardi E, Pettini P, Zaffaroni M, Giunti D, Capello E, Bernardi G, Ciusani E, Giannotta C, Nobile-Orazio E, Bazzigaluppi E, Passerini G, Bedin R, Sola P, Brivio R, Cavaletti G, Sala A, Bertolotto A, Desina G, Leone MA, Mariotto S, Ferrari S, Paternoster A, Giavarina D, Lolli F, Franciotta D.

Neurol Sci. 2017 Oct;38(Suppl 2):217-224. doi: 10.1007/s10072-017-3034-2. Review.

PMID:
29030765
27.

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Lechner-Scott J, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Solaro C, Grand'Maison F, Hupperts R, Prevost J, Sola P, Ferraro D, Terzi M, Butler E, Slee M, Kermode A, Fabis-Pedrini M, McCombe P, Barnett M, Shaw C, Hodgkinson S, Butzkueven H; MSBase Study Group.

Mult Scler. 2018 Oct;24(12):1617-1626. doi: 10.1177/1352458517728812. Epub 2017 Aug 31. Erratum in: Mult Scler. 2017 Dec;23(14):NP1.

PMID:
28857680
28.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand'Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.

Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

29.

Transcriptomic analysis of purified human cortical microglia reveals age-associated changes.

Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, Veras MM, Pereira TF, Leite REP, Möller T, Wes PD, Sogayar MC, Laman JD, den Dunnen W, Pasqualucci CA, Oba-Shinjo SM, Boddeke EWGM, Marie SKN, Eggen BJL.

Nat Neurosci. 2017 Aug;20(8):1162-1171. doi: 10.1038/nn.4597. Epub 2017 Jul 3.

PMID:
28671693
30.

Definitive childlessness in women with multiple sclerosis: a multicenter study.

Ferraro D, Simone AM, Adani G, Vitetta F, Mauri C, Strumia S, Senesi C, Curti E, Baldi E, Santangelo M, Montepietra S, Immovilli P, Guareschi A, Neri W, Granella F, Caniatti L, Tola MR, Motti L, Pesci I, Montanari E, Sola P.

Neurol Sci. 2017 Aug;38(8):1453-1459. doi: 10.1007/s10072-017-2999-1. Epub 2017 May 24.

PMID:
28536948
31.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
32.

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.

Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M.

Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.

PMID:
28382837
33.

A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band.

Ferraro D, Franciotta D, Bedin R, Solaro C, Cocco E, Santangelo M, Immovilli P, Gajofatto A, Calabrese M, Di Filippo M, Orlandi R, Simone AM, Vitetta F, Capello E, Giunti D, Murialdo A, Frau J, Mariotto S, Gallina A, Gasperini C, Sola P; RIREMS group (Rising Italian Researchers in Multiple Sclerosis).

J Neurol. 2017 May;264(5):973-978. doi: 10.1007/s00415-017-8480-5. Epub 2017 Apr 5.

PMID:
28382419
34.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
35.

Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis.

Bianchini E, De Biasi S, Simone AM, Ferraro D, Sola P, Cossarizza A, Pinti M.

Immunol Lett. 2017 Mar;183:1-7. doi: 10.1016/j.imlet.2017.01.009. Epub 2017 Jan 21. Review.

PMID:
28119072
36.

iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles.

De Biasi S, Simone AM, Nasi M, Bianchini E, Ferraro D, Vitetta F, Gibellini L, Pinti M, Del Giovane C, Sola P, Cossarizza A.

Front Immunol. 2016 Nov 30;7:555. eCollection 2016.

37.

Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome.

Ferraro D, Galli V, Simone AM, Bedin R, Vitetta F, Merelli E, Nichelli PF, Sola P.

J Neurovirol. 2017 Apr;23(2):329-334. doi: 10.1007/s13365-016-0493-9. Epub 2016 Nov 22.

PMID:
27878471
38.

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3.

PMID:
27810919
39.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.

Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Grammond P, Hupperts R, Grand'Maison F, Sola P, Pucci E, Bergamaschi R, Oreja-Guevara C, Van Pesch V, Ramo C, Spitaleri D, Iuliano G, Boz C, Granella F, Olascoaga J, Verheul F, Rozsa C, Cristiano E, Flechter S, Hodgkinson S, Amato MP, Deri N, Jokubaitis V, Spelman T, Butzkueven H, Kalincik T; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):196-203. doi: 10.1136/jnnp-2016-313976. Epub 2016 Sep 28.

PMID:
27683916
40.

Defining secondary progressive multiple sclerosis.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group.

Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.

PMID:
27401521
41.

Predictors of long-term disability accrual in relapse-onset multiple sclerosis.

Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D, Duquette P, Girard M, Prat A, Izquierdo G, Grammond P, Van Pesch V, Pucci E, Grand'Maison F, Hupperts R, Granella F, Sola P, Bergamaschi R, Iuliano G, Spitaleri D, Boz C, Hodgkinson S, Olascoaga J, Verheul F, McCombe P, Petersen T, Rozsa C, Lechner-Scott J, Saladino ML, Farina D, Iaffaldano P, Paolicelli D, Butzkueven H, Lugaresi A, Trojano M; MSBase Study Group.

Ann Neurol. 2016 Jul;80(1):89-100. doi: 10.1002/ana.24682. Epub 2016 Jun 1.

PMID:
27145331
42.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H.

Neurol Clin Pract. 2016 Apr;6(2):102-115.

43.

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermode A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group.

Mult Scler. 2017 Feb;23(2):266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11.

PMID:
27055805
44.

Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy.

Loraschi A, Bellantonio P, Bortolon F, Capra R, Cavalla P, Costantino G, Lugaresi A, Martinelli V, Marrosu MG, Patti F, Rottoli M, Salvetti M, Sola P, Solaro C, Klersy C, Marino F, Zaffaroni M, Cosentino M.

Neurol Sci. 2016 Apr;37(4):613-22. doi: 10.1007/s10072-016-2519-8. Epub 2016 Feb 19.

PMID:
26895323
45.

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database.

Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11.

PMID:
26362907
46.

Synthesis of novel sulfonamide analogs containing sulfamerazine/sulfaguanidine and their biological activities.

Aday B, Sola P, Çolak F, Kaya M.

J Enzyme Inhib Med Chem. 2016 Dec;31(6):1005-10. doi: 10.3109/14756366.2015.1079183. Epub 2015 Aug 31.

PMID:
26327456
47.

Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.

Ferraro D, Mirante VG, Losi L, Villa E, Simone AM, Vitetta F, Federzoni L, Nichelli PF, Sola P.

Neurologist. 2015 Jun;19(6):153-4. doi: 10.1097/NRL.0000000000000029.

PMID:
26075468
48.

Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis.

Ferraro D, Galli V, Vitetta F, Simone AM, Bedin R, Del Giovane C, Morselli F, Filippini MM, Nichelli PF, Sola P.

J Neuroimmunol. 2015 Jun 15;283:64-9. doi: 10.1016/j.jneuroim.2015.04.011. Epub 2015 Apr 25.

PMID:
26004159
49.

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. Erratum in: JAMA Neurol. 2015 Aug;72(8):950.

50.

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.

JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200.

PMID:
24977406

Supplemental Content

Support Center